Clinical trials revealed that systemic administration of B-cell-depleting anti-CD20 antibodies can hold lesion formation in the early relapsing-remitting phase of multiple sclerosis (MS). Throughout the secondary-progressive (SP) course of MS, pathogenic B cells may, however, progressively replicate within the central nervous system (CNS) itself, which is largely inaccessible to systemic anti-CD20 treatment. Utilizing the murine MS model of experimental autoimmune encephalomyelitis, we show that intrathecal (i.t.) administration of anti-CD20 alone very efficiently depletes meningeal B cells from established CNS lesions. In SP-MS patients, adding i.t. administration of anti-CD20 to its systemic use may be a valuable strategy to target pathogenic B-cell function.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184778 | PMC |
| http://dx.doi.org/10.1002/acn3.71 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Obinutuzumab May Be an Effective and Safe Option for Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis Patients after Multitarget Therapy Including Rituximab.
Am J Nephrol
October 2024
Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Article Synopsis
- Rituximab is effective for treating minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) in patients with frequently relapsing nephrotic syndrome, but does not work for everyone, particularly those with rapid relapses or no remission after treatment.
- This study analyzed the use of obinutuzumab, a new anti-CD20 antibody, in 11 adult patients who had not responded well to standard treatments, focusing on relapse rates and safety.
- Results indicated that obinutuzumab was mostly effective, with a median relapse-free time of over 12 months and more than half of the patients able to stop using corticosteroids and other immunosuppressants within three months, although
Patient-Specific Nanoparticle Targeting in Human Leukemia Blood.
ACS Nano
October 2024
Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria 3000, Australia.
Article Synopsis
- Researchers developed a model to study how well targeted nanoparticles, specifically anti-CD20-functionalized poly(ethylene glycol) (PEG) particles, can track and attack chronic lymphocytic leukemia (CLL) cells in patients' blood, showing significant variability in effectiveness among individuals.
- The study found that while these nanoparticles generally targeted CLL cells effectively, there was up to 234-fold difference in targeting efficacy and considerable off-target effects, killing almost all monocytes in a short period.
- Anti-PEG antibodies in patients' blood were identified as important factors affecting how well the nanoparticles targeted CLL cells, alongside other factors like cell antigen expression and nanoparticle properties, highlighting the complexity of personalized medicine in cancer treatment.
High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy.
Front Immunol
October 2024
Group of Advanced Immuno-Regulation (GIRA), Gregorio Marañon Health Research Institute Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Hospital General Gregorio Marañon, Madrid, Spain.
Introduction: Immunotherapy has revolutionized cancer treatment, and Chimeric Antigen Receptor T cell therapy (CAR-T) is a groundbreaking approach. Traditional second-generation CAR-T therapies have achieved remarkable success in hematological malignancies, but there is still room for improvement, particularly in developing new targeting strategies. To address this limitation, engineering T cells with multi-target universal CARs (UniCARs) based on monomeric streptavidin has emerged as a versatile approach in the field of anti-tumor immunotherapy.
View Article and Find Full Text PDFA personalized approach for anti-CD20 therapies in multiple sclerosis.
Mult Scler Relat Disord
November 2024
MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
Article Synopsis
- * Ongoing randomized controlled trials are exploring different approaches to dosing ocrelizumab, including higher doses, personalized B-cell dosing, and potential treatment discontinuation.
- * The proposed roadmap aims to use trial outcomes to improve understanding and effectiveness of anti-CD20 therapies, addressing existing knowledge gaps in MS treatment.
Evaluation of anti-vector immune responses to adenovirus-mediated lung gene therapy and modulation by αCD20.
Mol Ther Methods Clin Dev
September 2024
Departments of Pediatrics & Medicine, Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Although the last decade has seen tremendous progress in drugs that treat cystic fibrosis (CF) due to mutations that lead to protein misfolding, there are approximately 8%-10% of subjects with mutations that result in no significant CFTR protein expression demonstrating the need for gene editing or gene replacement with inhaled mRNA or vector-based approaches. A limitation for vector-based approaches is the formation of neutralizing humoral responses. Given that αCD20 has been used to manage post-transplant lymphoproliferative disease in CF subjects with lung transplants, we studied the ability of αCD20 to module both T and B cell responses in the lung to one of the most immunogenic vectors, E1-deleted adenovirus serotype 5.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!